Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
- 1 June 1998
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 17 (6) , 447-453
- https://doi.org/10.1007/bf01691581
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issueEuropean Respiratory Journal, 1995
- In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and-resistant Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 1995
- Quinolone Activity against AnaerobesDrugs, 1995
- In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobialDiagnostic Microbiology and Infectious Disease, 1994
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneAntimicrobial Agents and Chemotherapy, 1993
- Antibacterial Therapy for Lower Respiratory Tract Infections in Adults: A ReviewClinical Infectious Diseases, 1992
- The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unitRespiratory Medicine, 1992
- New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for TherapyMedicine, 1990